Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NSAIDs and congenital defects

This article was originally published in The Tan Sheet

Executive Summary

Women who take non-steroidal anti-inflammatory drugs during their first trimester may be more likely to give birth to babies with congenital defects, especially cardiac septal defects, according to a study in August's Birth Defects Research Part B. "Many pregnant women get prescriptions for NSAIDs during their first trimester, and even more - up to 15% - take over-the-counter versions of these drugs," an Aug. 24 press release states. Benjamin Ofori, MD, Sainte-Justine Hospital, Montreal, Quebec, Canada, et al., gathered information from three Quebec administrative databases and included 36,387 pregnant women in their nested case-control study. Among the 1,056 women who filled a prescription for NSAIDs early in their pregnancy, 8.8% had babies with congenital anomalies, the study finds. Of the 35,331 women who did not fill prescriptions for NSAIDs, 7% had congenital anomalies, according to the study. Additionally, the study found the proportion of infants with multiple congenital anomalies among mothers who filled an NSAID prescription in the first trimester was 16.1% compared to 14.2% for those who did not...

You may also be interested in...

Amgen/AstraZeneca’s Tezepelumab Cuts Asthma Exacerbations By 56%

Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics. 

Sarepta’s Next-Generation Drugs Draw Attention Amid ‘Incremental’ Approval

The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.

COVID-19 Will Forever Change Workplace, But Not Necessarily For The Better, Merck’s Frazier Says

Limiting interactions to two-dimensional settings will hinder collaboration, innovation and the mentoring of younger employees, Merck & Co. CEO Kenneth Frazier says. Frazier, who will retire in June, is looking forward to returning to public service but says "politics with a capital P is not my thing."





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts